Abstract 4008: Adaptive Servo Ventilation Improves Cardiac Dysfunction in Heart Failure Patients With Cheyne-Stokes Respiration
Background: Cheyne-Stokes respiration (CSR) associated with central sleep apnea deteriorates the prognosis of patients with heart failure (HF). However, it still remains unclear whether adaptive servo ventilation (ASV) for CSR improves cardiac function of patients with HF.
Methods: Twenty-six patients with HF and CSR (mean age 56.6±14.7 years, all males, mean ejection fraction 38.6±17.1%, mean apnea hypopnea index 39.1±13.2 times/hr, mean central apnea index 24.7±14.4 times/hr) were enrolled in this study and randomly divided into 2 groups: 12 patients treated with conventional medications for HF and ASV (ASV group) and 14 patients treated by conventional medications without ASV (Non-ASV group). Plasma B-type natriuretic peptide (BNP) levels, left ventricular ejection fraction (LVEF), LV mass index (LVMI) and left atrial volume index (LAVI) were determined before, 3 and 6 months after treatments in each group.
Results: In ASV group, plasma BNP levels were significantly decreased (P<0.05), and LVEF (P<0.01) was significantly increased after 6 months treatments with ASV. Furthermore, LVMI (P<0.05) and LAVI (P<0.05) were significantly reduced after 6 months with ASV treatment. In contrast, BNP, LVEF, LVMI and LAVI did not change in Non-ASV group.
Conclusions: Adaptive servo ventilation improved LV function, regressed LV mass, and reduced LA chamber size in HF patients with Cheyne-Stokes respiration.